Stock VTRS VIATRIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Viatris Inc.

Equities

VTRS

US92556V1061

Market Closed - Nasdaq
Other stock markets
 16:15:00 2024-05-03 EDT 		5-day change 1st Jan Change
11.78 USD +1.55% Intraday chart for Viatris Inc. +1.82% +8.77%
04-18 Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says MT
04-18 UK Regulator to Consider Undertakings for Theramex-Viatris Deal MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Viatris to Participate in the BofA Securities 2024 Health Care Conference
PR
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
PR
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
PR
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
AQ
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
PR
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
AQ
Pharma deal could reduce choice and lead to higher prices for HRT treatments
AQ
Viatris Announces the Launch of RYZUMVl 0.75% in the United States
AQ
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
AQ
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
PR
Viatris : Statement Regarding the Transaction with Insud Pharma
PU
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
PR
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
BU
Viatris: Q4 Earnings Snapshot
AQ
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
PR
Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results
PR
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference
PR
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer
PR
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders
PR
Acquisition deal to back European biosimilars market
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VTRS Stock
  4. News Viatris Inc.
  5. Press Releases